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Significance of this study
What is already known on this subject?
 ► Recurrence after successful treatment of 
Clostridium difficile infection (CDI) occurs in 
approximately one in four patients.
 ► Patients are typically frail with multiple 
comorbidities.
 ► A pilot study suggested that a course of 
rifaximin after successful treatment might 
reduce recurrence by around 50%.
What are the new findings?
 ► Rifaximin ‘follow-on’ treatment 400 mg 
three times a day for 2 weeks, followed by 
200 mg three times a day for 2 weeks, reduced 
recurrence by around 50%, but the 95% CI 
spans from 70% relative reduction to no effect.
 ► Meta-analysis suggests rifaximin ‘follow-on’ 
treatment is effective.
How might it impact on clinical practice in the 
foreseeable future?
 ► Rifaximin could be a useful additional 
therapeutic option to reduce recurrence of CDI 
but larger studies would increase confidence in 
its use.
AbSTrACT
background clostridium difficile infection (cDi) recurs 
after initial treatment in approximately one in four 
patients. a single-centre pilot study suggested that this 
could be reduced using ’follow-on’ rifaximin treatment. 
We aimed to assess the efficacy of rifaximin treatment in 
preventing recurrence.
Methods a multisite, parallel group, randomised, 
placebo controlled trial recruiting patients aged ≥18 
years immediately after resolution of cDi through 
treatment with metronidazole or vancomycin. 
Participants received either rifaximin 400 mg three times 
a day for 2 weeks, reduced to 200 mg three times a day 
for a further 2 weeks or identical placebo. the primary 
endpoint was recurrence of cDi within 12 weeks of trial 
entry.
results Between December 2012 and March 2016, 
151 participants were randomised to either rifaximin 
or placebo. Primary outcome data were available on 
130. Mean age was 71.9 years (SD 15.3). recurrence 
within 12 weeks was 29.5% (18/61) among participants 
allocated to placebo compared with 15.9% (11/69) 
among those allocated to rifaximin, a difference between 
groups of 13.7% (95% ci −28.1% to 0.7%, p=0.06). 
the risk ratio was 0.54 (95% ci 0.28 to 1.05, p=0.07). 
During 6-month safety follow-up, nine participants died 
in each group (12%). adverse event rates were similar 
between groups.
Conclusion While ’follow-on’ rifaximin after cDi 
appeared to halve recurrence rate, we failed to reach our 
recruitment target in this group of frail elderly patients, 
so the estimated effect of rifaximin lacks precision. a 
meta-analysis including a previous trial suggests that 
rifaximin may be effective; however, further, larger 
confirmatory studies are needed.
InTroduCTIon
Clostridium difficile infection (CDI) is one of the 
most common nosocomial infections in the devel-
oped world. Oral metronidazole or vancomycin 
has been widely used as primary treatment, with 
a variable cure rate of 70%–90% in most series, 
but 15%–30% of patients suffer a recurrence 
in the following months,1–3 with higher rates in 
observational studies.4–7 Predictors of recurrence 
include advanced age, detection of toxin in stool 
and persistence of diarrhoea beyond the fourth day 
of treatment8 along with the presence of hepatic 
and renal disease,9 disease severity10 and concom-
itant antibiotic therapy.11 
A diverse commensal colonic microbiota is 
believed to confer resistance to CDI but the 
common treatments used to date, vancomycin and 
metronidazole, further deplete the microbiota.12–14 
The importance of this depletion in causing recur-
rence is strongly supported by the success of faecal 
transplantation in treating recurrent disease.15 16 
Newer agents with more selective effects on the gut 
microbiota such as fidaxomicin,17 18 cadazolid19 and 
ridinilalzole20 or monoclonal antibodies designed 
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to neutralise C. difficile toxins (CDTs) such as bezlotoxumab21 
show some reduction in recurrence rates.15 16
Rifaximin is a rifamycin derivative, similar to rifampicin, with 
a broad spectrum of antimicrobial activity including C. difficile. 
It was designed to be highly insoluble in water with very low 
bioavailability. It is widely used to treat traveller’s diarrhoea,22 
hepatic encephalopathy23 and irritable bowel syndrome24 as well 
as for CDI treatment and recurrence prevention25–27 and has an 
excellent safety record.28 Minimal absorption occurs after inges-
tion so that the drug is highly concentrated in the gut lumen. Bile 
increases solubility 70-fold to 120-fold, so effective concentra-
tions should be maximal in the distal small bowel and proximal 
colon, the site of C. difficile germination.29 Theoretically, rifax-
imin should suppress C. difficile proliferation while commensals 
recover to re-establish an environment hostile to the pathogen. 
Studies in hepatic encephalopathy, colitis and irritable bowel 
syndrome support this by showing little overall impact of regular 
rifaximin on the faecal microbiota.30–32
One previous randomised controlled trial suggested that a 
course of rifaximin after successful primary treatment with 
vancomycin or metronidazole might reduce the likelihood of 
recurrence, but with only 68 participants, the estimated treat-
ment effect was imprecise.27
The aim of the RAPID (RifAximin for the Prevention of 
recurrence following standard treatment of Infection with Clos-
tridium Difficile) trial was to assess whether treatment with 
rifaximin after CDI resolution with standard therapy reduced 
the rate of CDI recurrence compared with placebo.
MeTHodS
Trial design and oversight
RAPID was a multisite, two arm, parallel group, blinded, 
randomised, placebo controlled trial conducted in 23 secondary 
care hospitals in England with hospital microbiology services 
that also provided for the local community. The study was 
conducted in accordance with Good Clinical Practice guidelines 
and the provisions of the Declaration of Helsinki. The trial was 
prospectively registered on a public database: EU Clinical Trials 
Register EudraCT 2012-003205-10.
recruitment
Participants were recruited between 11 December 2012 and 7 
March 2016. Those eligible for inclusion (see online supplemen-
tary file 1) were adults aged 18 years or older with a confirmed 
case of CDI that was successfully treated with metronidazole 
or vancomycin. This included primary, recurrent and multiply 
recurrent CDI episodes. CDI was defined as an episode of loose 
stools in the presence of a positive stool assay for glutamate 
dehydrogenase (GDH) and enzyme immunoassay for CDT with 
or without a positive C. difficile culture. Endoscopic evidence of 
pseudomembranous colitis could substitute for toxin positivity. 
In May 2014, the protocol was amended to remove the require-
ment for a GDH assay to reflect new guidance from Public 
Health England. Successful treatment for CDI was defined as 
cessation of diarrhoea for two or more days with no loose stools: 
stools that took the shape of a container, corresponding to type 
6 or 7 on the Bristol Stool Form Scale.
Participants were recruited from primary care through 
their general practitioner and secondary care through hospital 
research teams. Patients testing positive for C. difficile were 
identified through central laboratory testing. All participants 
with capacity gave written informed consent. Where prospec-
tive participants lacked capacity to give consent, consent could 
be given by a designated legal representative or an independent 
health advocate in accordance with Schedule 1 of the Medicines 
for Human Use (ClinicalTrials) Regulations 2004.
randomisation and blinding
Patients were randomised within 5 days of the last dose of stan-
dard therapy and were started the same day on the study drug 
which was continued for the next 4 weeks. Participants were 
randomly assigned in a 1:1 ratio to receive rifaximin or placebo. 
Randomisation was stratified by hospital and used a computer 
generated pseudorandom code, using random permuted blocks 
of randomly varying size. Site research teams allocated partici-
pants to a treatment using a secure, internet-based randomisa-
tion system developed and maintained by Nottingham Clinical 
Trials Unit, ensuring allocation concealment.
Participants, clinicians, research nurses and the study team 
were blind to the allocated treatment as active and placebo 
tablets were packaged in matching deidentified treatment packs 
and dispensed by the hospital pharmacy.
Intervention
Participants were given 126 tablets, containing either rifax-
imin 200 mg or an identical placebo formulation. Rifaximin 
and placebo were supplied by Norgine Pharmaceuticals 
Limited as a gift and manufactured by Alfa Wassermann. The 
intended treatment regime was two tablets (400 mg rifaximin) 
taken three times a day for 14 days, reduced to one tablet 
(200 mg) three times a day for a further 14 days. Participants 
continued to receive standard care, including antibiotics for 
indications other than CDI, as determined by their physician. 
The number of tablets taken was assessed from the difference 
between the number of tablets supplied (126) and the number 
returned at the week 4 visit or earlier if CDI recurred. Since 
recurrences meant that participants took drug for a variable 
duration, compliance was assessed against the number of 
tablets expected to be taken by each participant at the end of 
their involvement.
Participants with recurrence of CDI within 28 days of recruit-
ment were asked to provide stool samples and withdrawn from 
trial treatment prior to commencing standard therapy at the 
local Principle Investigator’s discretion. Additional samples were 
also collected during any diarrhoea episode and for any recur-
rences occurring later after the start of treatment intervention up 
to 6 months follow-up.
Follow-up
Participants attended study visits at 4 weeks and 12 weeks after 
the start of intervention, with telephone contact at 2 weeks, 
8 weeks and 6 months to identify CDI recurrence and any serious 
adverse events (SAEs). In addition, patients were tagged in 
microbiology laboratory reporting systems and hospital admin-
istration systems to flag any CDI recurrence or hospital admis-
sion. Recruitment was slower than anticipated. Despite applying 
for and obtaining a further grant to fund a 12-month extension, 
we were unable to achieve our target recruitment by the time 
the trial was forced to close to follow-up in July 2016, when 
all funding ceased. An amendment to maximise numbers for 
the primary outcome was made, so any participants recruited 
after 10 December 2015 did not receive a 6-month telephone 
follow-up. For these participants, their last visit occurred at 
week 12, allowing determination of the primary outcome.
 o
n
 8 August 2019 at Liverpool University. Protected by copyright.
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2018-316794 on 25 September 2018. Downloaded from 
1226 Major g, et al. Gut 2019;68:1224–1231. doi:10.1136/gutjnl-2018-316794
Colon
Figure 1 Participant flow through the study.
outcomes
The primary outcome was CDI recurrence within 12 weeks 
of randomisation. A recurrence was defined as three or more 
loose stools for two or more days in conjunction with a posi-
tive stool toxin assay. The primary outcome was determined by 
research nurses in each site confirming stool frequency with the 
study subject by direct questioning, together with the laboratory 
results.
Secondary outcomes were: (1) recurrence of CDI within 
6 months; (2) rehospitalisation for CDI within 6 months; (3) 
length of in-hospital stay following start of trial medication. We 
checked the hospital record of those who were lost to follow-up 
to ensure no further C. difficile infections or deaths were missed.
Our initial intention to record stool frequency and consis-
tency during the 4 weeks of treatment through daily stool diaries 
was made optional in June 2013 as we found early on that this 
requirement caused some patients to decline participation so 
these outcomes became exploratory. Similarly stool samples 
other than at the time of possible recurrence were made optional 
to maximise recruitment and retention.
Safety
European Medicines Agency requirements for additional moni-
toring of the rifaximin formulation used in the trial mandated 
statutory reporting of all adverse events (AEs) even when such 
events are clinical endpoints in a trial. All AEs documented up 
to 30 days after the last dose of IMP were reported. For serious 
adverse events, including rehospitalisation due to CDI, the 
reporting window extended to final follow-up.
Sample size and statistical methods
Prior data indicated that the CDI recurrence rate among controls 
would be 30%. A clinically important difference was consid-
ered to be 20% (ie, 10% recurrence on rifaximin). To detect 
this difference with 80% power and two-sided 5% significance 
level (type I error) required 72 participants per arm (144 in 
total) using a two-group continuity corrected χ² test. The target 
sample size of 180 was chosen to allow for up to 20% non-col-
lection of the primary outcome.
Analyses were carried out using Stata/SE 13.1. All analyses 
were conducted according to allocated group (placebo or rifax-
imin) regardless of the amount of tablets actually taken. The 
primary analysis estimated the difference in percentage CDI 
recurrence between rifaximin and placebo groups at 12 weeks 
without imputation of missing outcome data. A generalised esti-
mating equation was used with binomial family, identity link and 
an exchangeable correlation matrix to account for randomisa-
tion being stratified by hospital.33 The between-group estimate 
is presented as a risk difference with 95% CI and p value. The 
relative risk of CDI recurrence within 12 weeks is also presented 
(estimated using similar methods).
Sensitivity analyses for the primary outcome were performed 
looking at the effect of missing data and compliance (see 
online supplementary file 3). A planned subgroup analysis for 
the primary outcome according to antibiotic use at baseline 
(metronidazole or vancomycin) was performed by including an 
interaction term in the primary analysis model. An additional 
posthoc analysis for the primary outcome according to history 
of CDI was also performed using the same methods.
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Table 1 Baseline characteristics
Placebo
(n=74)
rifaximin
(n=77)
Total
(n=151)
Age at randomisation
  Mean (SD) 71.5 (14.8) 72.2 (15.8) 71.9 (15.3)
  Median (25th, 75th 
centile)
75 (63, 81) 76 [63, 85) 76 (63, 83)
  Min, max 26, 96 35, 95 26, 96
Gender
  Male 29 (39%) 38 (49%) 67 (44%)
  Female 45 (61%) 39 (51%) 84 (56%)
Ethnicity 
  White 73 (99%) 76 (99%) 149 (99%)
  Indian 1 (1%) 1 (1%) 2 (1%)
  Participant recruited from
  Hospital 64 (86%) 57 (74%) 121 (80%)
  Home 10 (14%) 20 (26%) 30 (20%)
  Inpatient at start of 
treatment*
25 (34%) 29 (38%) 54 (36%)
Antibiotic used to treat initial CDI
  Metronidazole 27 (36%) 31 (40%) 58 (38%)
  Vancomycin 47 (64%) 46 (60%) 93 (62%)
  Dose tapered
  Yes 4 (5%) 5 (6%) 9 (6%)
CDI history
  First episode of CDI 61 (82%) 57 (74%) 118 (78%)
  Previously diagnosed 
with CDI
9 (12%) 11 (14%) 20 (13%)
  Unknown 4 (5%) 9 (12%) 13 (9%)
  Number of previous CDI 
cases—min, max
1, 5 1, 2 1, 5
Body mass index
  Mean (SD) 24.7 (5.7) 25.5 (6.3) 25.1 (6.0)
  Median (25th, 75th 
centile)
24 (20.3, 28) 24.5 (21.1, 27.3) 24.3 (20.7, 27.7)
  Min, max 14.4, 44.6 14.3, 44.9 14.3, 44.9
  N 64 68 132
Medication
  Proton pump inhibitor 
taken in 30 days prior to 
randomisation
15 (20%) 25 (32%) 40 (26%)
  Additional antibiotics 
being taken at 
randomisation
5 (7%) 3 (4%) 8 (5%)
All data are n (%) unless otherwise specified.
*Note not all participants recruited from hospital were inpatients at the start of 
treatment. Participants could be discharged from hospital with an ongoing course of 
standard therapy for C. difficile. The baseline/randomisation visit was then arranged 
for between 0 and 5 days postcompletion of standard therapy.
CDI, Clostridium difficile infection.
Table 2 Analysis of primary outcome: CDI recurrence within 12 
weeks
Placebo
(n=74)
rifaximin
(n=77)
risk difference
(95% CI, p values)
Main analysis: available case
  Primary outcome 
data available
61 69
  No recurrence 43 (70.5%) 58 (84.1%)
  Recurrence 18 (29.5%) 11 (15.9%) −13.7% (−28.1% to 0.7%,
p=0.06)
Number of participants with primary outcome data available is used as the 
denominator for CDI recurrence.
Risk difference/risk ratio and 95% CIs calculated using generalised estimating 
equations (with an exchangeable correlation matrix to account for hospital) using 
the Binomial family.
CDI, Clostridium difficile infection.
Figure 2 Kaplan-Meier curves of time to CDI recurrence during 
trial. The figure shows most relapses in the rifaximin group occurred 
between 50 and 100 days. Recurrence in the placebo group mostly 
occurred earlier. CDI, Clostridium difficile infection.
CDI recurrence at 6 months and rehospitalisation for CDI 
at 6 months were analysed using the same method as for the 
primary outcome. Length of stay was compared between the two 
groups using a Cox proportional hazards model.
The time to first CDI recurrence is also presented using 
Kaplan-Meier survival curves. Participants who did not have a 
CDI recurrence are censored at date of death for participants who 
died, date of withdrawal for participants who withdrew consent 
and otherwise at 184 days (ie, 6 months) if randomised before 
the 10 December 2015 and 84 (ie, 12 weeks) if randomised after 
10 December 2015.
Adherence with trial treatment, other antibiotic use, AEs and 
stool frequency and consistency are presented descriptively. AEs 
were summarised according to date of onset: starting up to 28 
days postrandomisation (ie, during the treatment period) and 
starting 29 days or more after randomisation.
Patient involvement
The Nottingham Digestive Diseases Centre Patient Advisory 
Group helped to prioritise the research question, plan the study 
and design all written material. A group delegate was a member 
of the Trial Steering Committee.
reSulTS
recruitment and retention
A total of 2157 patients were screened across 23 hospitals. Of 
these, 151 were eligible, willing and randomised (7% of those 
screened) before funding limits were reached (74 placebo, 77 
rifaximin). Approximately one-third of patients approached 
were not eligible for the trial and 20% declined to take part. 
The most common reasons given were competing comorbidities, 
perceived increase to treatment burden and personal demands 
of trial participation. Other reasons for exclusion reported were 
death or clinical judgement that the patient was too unwell.
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Table 3 Secondary outcomes of recurrence of CDI within 6 months and length of initial in hospital stay
Placebo
(n=74)
rifaximin
(n=77)
Intervention effect
(95% CI)
Recurrence of CDI within 6 months
  Data available 61 66 
  No recurrence 41 (67.2%) 52 (78.8%) Risk difference Risk ratio
  Recurrence 20 (32.8%) 14 (21.2%) −11.6% (−27.0% to 3.7%) 0.65 (0.36, 1.16)
Risk difference Risk ratio
  Hospitalisation for recurrence 8 (13.1%) 9 (13.6%) 0.5% (−11.1% to 12.0%) 1.04 (0.43 to 2.52)
  Total number of recurrences
   1 17 12
   2 1 1
   3 2 1
Length of in hospital stay following start of treatment
  Inpatient at start of treatment 25 29
  Discharged on the same day as start of treatment 4 2
  Withdrew consent on the same day as randomisation 0 1
HR
  Median length of stay (95% CI) 21 (4 to 29) 15 (6 to 40) 0.94 (0.52 to 1.71)
  n 21 26
Number of participants with 6 months outcome data available is used as the denominator for recurrence and hospitalisation for recurrence.
Risk difference/risk ratio and 95% CIs calculated using generalised estimating equations (to account for hospital) using the Binomial family.
Median length of stay based on Kaplan Meier survival estimates.
Unadjusted HR for length of in hospital stay is reported as the shared frailty model used to account for stratification by site did not converge.
CDI, Clostridium difficile infection. 
The target sample size of 180 was not met before the trial 
reached its funding limit and ceased recruitment in March 2016. 
The last follow-up visit occurred in July 2016.
Participant flow through the trial is shown in figure 1. The 
primary outcome was available for 61 of the 74 participants 
randomised to the placebo group (82%) and 69 of the 77 partic-
ipants randomised to the rifaximin group (90%). Fifteen partici-
pants withdrew consent and six participants died before primary 
outcome data could be collected.
baseline characteristics
Baseline data are shown in table 1. The mean age of partici-
pants was 71.9 years and 118 participants (78%) were recruited 
at their first episode of CDI. The rifaximin group contained a 
slightly higher proportion of men, participants taking a proton 
pump inhibitor at randomisation, participants with a previous 
episode of CDI and participants recruited outside hospital. Just 
over a third of participants were inpatients when the trial treat-
ment was started.
Adherence
Seventy-three participants (95%) in the rifaximin and 89% in the 
placebo group took at least one dose of trial medication. Median 
compliance was 97% (IQR 68%–100%) in the placebo arm and 
100% (IQR 94–100) in the rifaximin arm (see online supple-
mentary file 2).
Primary outcome
Eighteen of 61 participants (29.5%) on placebo had a recurrence 
of CDI within 12 weeks compared with 11 of 69 participants 
(15.9%) on rifaximin (table 2 and figure 2). The difference in 
risk of CDI recurrence within 12 weeks on rifaximin compared 
with placebo was −13.7% with 95% CI −28.1% to 0.7%, 
p=0.06 and risk ratio 0.54 (95% CI 0.28 to 1.05).
Secondary analyses
The results from the sensitivity analyses were similar to the 
primary analysis (online supplementary file 3): the difference 
in risk of CDI recurrence using multiple imputation for missing 
outcome data was −12.8% (95% CI −27.0% to 1.4%). Assuming 
all with missing data recurred gave a risk difference of −17.1% 
while assuming all with missing data did not recur gave a differ-
ence of −10.2% (see online supplementary file 3). There was no 
evidence of a differential treatment effect according to antibiotic 
used to treat the initial CDI or history of CDI (online supple-
mentary file 4).
At 6 months, the percentage of participants identified as having 
a CDI recurrence remained smaller in the rifaximin group but 
the magnitude of the difference in risk between the groups had 
reduced (table 3). Hospitalisation for CDI recurrence and length 
of inpatient stay for those participants who were inpatients at 
the start of treatment were similar in each group (table 3).
recurrence and its relation to further antibiotic use
Twenty-five out of 74 (34%) patients allocated to placebo and 
23/77 (30%) allocated to rifaximin received further courses of 
antibiotics during the study. Of these, 26% (19/74) and 21% 
(16/77) were for indications other than treatment of recur-
rent CDI. There was no obvious difference in recurrence rate 
following antibiotic use in the two treatment groups but the 
numbers are too small to be meaningful.
Assessment of safety
There were nine deaths reported on placebo and nine deaths 
on rifaximin. There were 15 (22%) participants with at least 
one SAE on placebo and 12 (16%) on rifaximin in the 28 days 
postrandomisation. No SAEs were considered to relate to the 
trial treatment in the group allocated to rifaximin. Non-SAEs in 
the 28 days postrandomisation were similar in the two groups 
but none were considered definitely related to rifaximin. Full 
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Figure 3 Combined data from current and previous trial showing a significant difference favouring rifaximin treatment.
details of types of AEs are provided in online supplementary files 
5 and 6.
Trial participation survey
Fifty six participants completed the patient experience question-
naire at 6 months. Barriers to taking part in the study identi-
fied by participants included difficulties completing the diary, 
collecting stool samples and taking the medication (size and 
quantity of tablets). At least one stool diary was completed by 75 
participants (50%) during weeks one to four and by 48 partic-
ipants (32%) in week 12. A summary of stool frequency and 
consistency during weeks 1 to 4 and weeks 11 to 12 is shown in 
online supplementary file 7.
MeTA-AnAlySIS
This is the second randomised, placebo controlled trial of 
‘follow-on’ rifaximin treatment to prevent recurrence of C. diffi-
cile infection. Both trials included patients successfully treated 
with either metronidazole or vancomycin and both tested 
4 weeks of rifaximin. The only difference was that in the current 
trial the rifaximin dose was tapered, using half the dose during 
the second 2-week period. However, the low absorption rate 
of rifaximin means that the stool concentration after standard 
doses exceeds the minimal inhibitory concentration (MIC) for 
C. difficile 160-fold34 so that halving the dose in the second 2 
weeks would still provide stool concentrations well above the 
MIC. Combining the data increased confidence in a true differ-
ence in outcome, favouring rifaximin treatment. Data synthesis 
is based on summary results from both trials rather than indi-
vidual patient data.
The first trial had 39 participants randomised to rifaximin 
and 40 to placebo. Participants who did not take any doses were 
excluded from analysis giving 33 and 35 participants with data 
on the primary endpoint while the numbers in the analysis for 
RAPID did not exclude participants who did not take any trial 
treatment We found that, compared with placebo, follow-on 
rifaximin reduced absolute CDI recurrence rate at 12 weeks by 
13.7% while the first trial27 reduced recurrence rate by 16%, 
giving an overall absolute reduction in risk of CDI recurrence of 
14% (95% CI −26% to −3%), p=0.01 (see figure 3).
dISCuSSIon
The results of this trial are consistent with the earlier study27 
suggesting that rifaximin treatment after resolution of C. difficile 
associated diarrhoea with standard therapy may reduce the risk 
of recurrence. However, like the earlier trial, the CI was wide 
and does not rule out no effect of rifaximin. Several studies have 
confirmed the underlying logic of the treatment showing that 
rifaximin does not alter the balance between commensal micro-
biota22 32 but does have significant activity against C. difficile. 
As figure 2 shows, the recurrences on placebo tended to occur 
rapidly, within the first few weeks, during which time those on 
rifaximin may have been protected from recurrence. A further 
course of antibiotics preceded recurrence in 9 out of the total 34 
recurrences. Given the small number of cases, it is not possible to 
state definitively whether rifaximin was protective against such 
a recurrence.
The reduction in recurrence rate we observed of 13.7% was 
less than the 20% we had assumed in our power calculations, 
which were in retrospect overoptimistic. However, it was similar 
to the reduction seen in trials of the monoclonal antibody bezlo-
toxumab as an adjunct to antibiotic therapy at primary treat-
ment35 and in two large trials of fidaxomicin18 36 although in 
those trials fidaxomicin was used for primary treatment. It is 
worth noting that in a recent meta-analysis three out of five 
studies of fidaxomicin’s use in recurring disease concluded it was 
cost effective even though the observed reductions were only 
8%–15%. A recent phase II trial found that primary treatment 
with ridinilazole, a novel antibiotic designed to avoid distur-
bance of the gut microbiota also reduced recurrence rate at 30 
days to a similar degree.20 However, our trial recruited patients 
who had responded to initial standard therapy so may represent 
a different population.
PPIs have been reported to increase recurrence rate, so it is 
important to note that patients on rifaximin by chance had a 
higher rate of PPI use, being 32% vs 20% in those on placebo 
which could have reduced the size of the reduction in recurrence 
rate we observed.
Deaths, SAEs and AEs were similar to placebo suggesting that 
rifaximin is safe in this elderly, frail population. Challenges to 
recruiting this population have been reported elsewhere37 and 
made performing the trial difficult: we required 23 sites and 
screened over 2000 patients. The main reason for non-enrol-
ment of those who met entry criteria was choice not to take part. 
This reflects the frailty and multiple comorbidities characteristic 
of patients with CDI whose infection has usually been induced 
by antibiotic treatment for another serious illness. Participants’ 
median (IQR) age of 76 (63, 83) with the oldest being 96, was 
higher than other trials cited. Mortality rate was also higher 
than in many trials of newer agents which tend to exclude the 
most frail. This suggests that, as we intended, by minimising 
the barriers to patient recruitment, we recruited a sample more 
typical of the patient group at risk of CDI, so our results should 
be generalisable to every day clinical practice.
A recent systematic review found that in Europe, the incre-
mental cost of C. difficile infection ranged from £4577 to 
£8843, driven primarily by increased length of hospital stay.38 
The course of rifaximin we used would cost around £200 at 
current UK pricing. Importantly, rifaximin has been widely 
used for three decades and is known to be safe, possibly related 
to its unusually low solubility and absorption. Resistance was 
initially uncommon but is due to a simple mutation in the rpoB-
gene which codes for rifaximin’s molecular target, RNA poly-
merase β subunit. Of concern is the fact that mutations in this 
gene also underlie resistance to both rifamycin and rifampicin, 
an important part of antimycobacterial treatment. It rapidly 
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appears in groups of patients where the drug is widely used, for 
example, treatment for hepatic encephalopathy.39 Its widespread 
use for IBS and hepatic encephalopathy in the USA has coincided 
with a marked rise of resistance from 8% to 35% in Texas.40 
Rifaximin’s use is more restricted in the UK and resistance is 
at present low. However, indiscriminate use in a wide range of 
infections will rapidly increase rates of resistance, so it should be 
reserved for those at high risk of recurrence. Those who expe-
rience multiple recurrences and have repeated courses of treat-
ments often have severely depleted microbiota and are probably 
best treated by non-antibiotic therapies particularly faecal trans-
plantation which has a high success rate in such patients.17
The main limitation of the trial is that the planned sample 
size was not achieved, resulting in reduced precision of the esti-
mated treatment effect. However, combining our data with the 
earlier trial in a meta-analysis shows a significant reduction in 
CDI recurrence of around 50%. This provides some evidence for 
its efficacy but larger trials are needed before the true effect size 
can be accurately estimated.
Correction notice this article has been corrected since it published Online First. 
an error in the Meta-analysis paragraph has been corrected.
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